"Hence, it is possible that the administration of allogeneic MSCs could accelerate the steps of tissue repair in the lungs, decreasing the need for further mesenchymal cell activation". (quote from the paper you linked)
Nice paper , thanks . I know I read this somewhere before , so i dug this up:
-Cents
Post by TimGDixon » Tue Jun 30, 2020 7:19 am
I thought i would take a minute to help you understand that there are two types of StemVacs - an autologous version and now an allogeneic version.
Autologous: Auto means self. The dendritic cells in autologous StemVacs come from the same person who will get the transplant, so the patient is their own donor.
Allogeneic: Allo means other. The dendritic cells in allogeneic StemVacs come from a person other than the patient, and in this case it is umbilical cord blood for the donor.
The reason we are *not* using autologous StemVacs in covid-19 is because of the risk factor to manufacture the immunotherapy using the patients own blood. High risk every step of the way, from drawing blood to transportation of it, and eventually using it to create the personalized drug. It also takes 8 days to mature the cells prior to injection. Covid-19 patients don't have 8 days - sometimes they don't have 8hrs.
Allogeneic StemVacs on the other hand is derived from cord blood and then processed using our proprietary manufacturing into StemVacs. Maybe we call this StemVacs2, i hadn't thought about it - but for sure they can be identified and distinguished now by their source.
This means this drug could be mass produced and be off-the-shelf on demand use rather than the protracted method of StemVacs1
News 
Market Data 
Discover 
